MedTrace Logo

A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)

NCT05058040 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2500

Last updated 2025-01-24

No results posted yet for this study

Summary

A clinical study to evaluate the long-term safety of Sodium Oligomannate Capsules (GV-971)

Conditions

  • Alzheimer Disease

Interventions

DRUG

Sodium Oligomannate Capsules

Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.

Sponsors & Collaborators

  • Green Valley (Shanghai) Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-02
Primary Completion
2025-01-31
Completion
2025-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05058040 on ClinicalTrials.gov